<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240811001215&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20240811001215&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 11 Aug 2024 04:12:15 +0000</lastbuilddate>
<pubDate>Sat, 10 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Angioscopic evaluation of the efficacy of a new excimer laser in in-stent occlusion of a drug eluting stent</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39126341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 10:ehae512. doi: 10.1093/eurheartj/ehae512. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39126341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39126341</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae512>10.1093/eurheartj/ehae512</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39126341</guid>
<pubDate>Sat, 10 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Takeo Horikoshi</dc:creator>
<dc:creator>Tsuyoshi Kobayashi</dc:creator>
<dc:creator>Akira Sato</dc:creator>
<dc:date>2024-08-10</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Angioscopic evaluation of the efficacy of a new excimer laser in in-stent occlusion of a drug eluting stent</dc:title>
<dc:identifier>pmid:39126341</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae512</dc:identifier>
</item>
<item>
<title>The need to diversify genomic studies: Insights from Andean highlanders and Amazonians</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>More globally diverse perspectives are needed in genomic studies and precision medicine practices on non-Europeans. Here, we illustrate this by discussing the distribution of clinically actionable genetic variants involved in drug response in Andean highlanders and Amazonians, considering their environment, history, genetic structure, and historical biases in the perception of biological diversity of Native Americans.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 30:S0092-8674(24)00769-4. doi: 10.1016/j.cell.2024.07.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">More globally diverse perspectives are needed in genomic studies and precision medicine practices on non-Europeans. Here, we illustrate this by discussing the distribution of clinically actionable genetic variants involved in drug response in Andean highlanders and Amazonians, considering their environment, history, genetic structure, and historical biases in the perception of biological diversity of Native Americans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121858</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.009>10.1016/j.cell.2024.07.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121858</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Isabela Alvim</dc:creator>
<dc:creator>Carolina Silva-Carvalho</dc:creator>
<dc:creator>Marla Mendes de Aquino</dc:creator>
<dc:creator>Victor Borda</dc:creator>
<dc:creator>Cesar Sanchez</dc:creator>
<dc:creator>Carlos Padilla</dc:creator>
<dc:creator>Omar Cáceres</dc:creator>
<dc:creator>Isabela Rezende-Diniz</dc:creator>
<dc:creator>Julia Saraiva-Duarte</dc:creator>
<dc:creator>Lucas Faria-Costa</dc:creator>
<dc:creator>Meddly L Santolalla</dc:creator>
<dc:creator>Fernanda Rodrigues-Soares</dc:creator>
<dc:creator>Camila Zolini</dc:creator>
<dc:creator>Adrián Llerena</dc:creator>
<dc:creator>Timothy D O'Connor</dc:creator>
<dc:creator>Robert H Gilman</dc:creator>
<dc:creator>Heinner Guio</dc:creator>
<dc:creator>Eduardo Tarazona-Santos</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The need to diversify genomic studies: Insights from Andean highlanders and Amazonians</dc:title>
<dc:identifier>pmid:39121858</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.009</dc:identifier>
</item>
<item>
<title>Stress-sensitive neural circuits change the gut microbiome via duodenal glands</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>Negative psychological states impact immunity by altering the gut microbiome. However, the relationship between brain states and microbiome composition remains unclear. We show that Brunner's glands in the duodenum couple stress-sensitive brain circuits to bacterial homeostasis. Brunner's glands mediated the enrichment of gut Lactobacillus species in response to vagus nerve stimulation. Cell-specific ablation of the glands markedly suppressed Lactobacilli counts and heightened vulnerability to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 1:S0092-8674(24)00779-7. doi: 10.1016/j.cell.2024.07.019. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Negative psychological states impact immunity by altering the gut microbiome. However, the relationship between brain states and microbiome composition remains unclear. We show that Brunner's glands in the duodenum couple stress-sensitive brain circuits to bacterial homeostasis. Brunner's glands mediated the enrichment of gut Lactobacillus species in response to vagus nerve stimulation. Cell-specific ablation of the glands markedly suppressed Lactobacilli counts and heightened vulnerability to infection. In the forebrain, we mapped a vagally mediated, polysynaptic circuit connecting the central nucleus of the amygdala to Brunner's glands. Chronic stress suppressed central amygdala activity and phenocopied the effects of gland lesions. Conversely, excitation of either the central amygdala or parasympathetic vagal neurons activated Brunner's glands and reversed the effects of stress on the gut microbiome and immunity. The findings revealed a tractable brain-body mechanism linking psychological states to host defense.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121857</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.019>10.1016/j.cell.2024.07.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121857</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Hao Chang</dc:creator>
<dc:creator>Matthew H Perkins</dc:creator>
<dc:creator>Leonardo S Novaes</dc:creator>
<dc:creator>Feng Qian</dc:creator>
<dc:creator>Tong Zhang</dc:creator>
<dc:creator>Peter H Neckel</dc:creator>
<dc:creator>Simon Scherer</dc:creator>
<dc:creator>Ruth E Ley</dc:creator>
<dc:creator>Wenfei Han</dc:creator>
<dc:creator>Ivan E de Araujo</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stress-sensitive neural circuits change the gut microbiome via duodenal glands</dc:title>
<dc:identifier>pmid:39121857</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.019</dc:identifier>
</item>
<item>
<title>Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8&lt;sup>;+&lt;/sup>; T cells to promote antitumor immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo to interrogate the immunologic mechanisms of rela+nivo. Analysis of biospecimens from this ongoing trial demonstrated that rela+nivo led to enhanced capacity for CD8^(+) T cell receptor signaling and altered CD8^(+) T cell differentiation, leading to heightened cytotoxicity...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4373-4388.e15. doi: 10.1016/j.cell.2024.06.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo to interrogate the immunologic mechanisms of rela+nivo. Analysis of biospecimens from this ongoing trial demonstrated that rela+nivo led to enhanced capacity for CD8<sup>+</sup> T cell receptor signaling and altered CD8<sup>+</sup> T cell differentiation, leading to heightened cytotoxicity despite the retention of an exhaustion profile. Co-expression of cytotoxic and exhaustion signatures was driven by PRDM1, BATF, ETV7, and TOX. Effector function was upregulated in clonally expanded CD8<sup>+</sup> T cells that emerged after rela+nivo. A rela+nivo intratumoral CD8<sup>+</sup> T cell signature was associated with a favorable prognosis. This intratumoral rela+nivo signature was validated in peripheral blood as an elevated frequency of CD38<sup>+</sup>TIM3<sup>+</sup>CD8<sup>+</sup> T cells. Overall, we demonstrated that cytotoxicity can be enhanced despite the retention of exhaustion signatures, which will inform future therapeutic strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121849/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121849</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.036>10.1016/j.cell.2024.06.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121849</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Anthony R Cillo</dc:creator>
<dc:creator>Carly Cardello</dc:creator>
<dc:creator>Feng Shan</dc:creator>
<dc:creator>Lilit Karapetyan</dc:creator>
<dc:creator>Sheryl Kunning</dc:creator>
<dc:creator>Cindy Sander</dc:creator>
<dc:creator>Elizabeth Rush</dc:creator>
<dc:creator>Arivarasan Karunamurthy</dc:creator>
<dc:creator>Ryan C Massa</dc:creator>
<dc:creator>Anjali Rohatgi</dc:creator>
<dc:creator>Creg J Workman</dc:creator>
<dc:creator>John M Kirkwood</dc:creator>
<dc:creator>Tullia C Bruno</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8&lt;sup>;+&lt;/sup>; T cells to promote antitumor immunity</dc:title>
<dc:identifier>pmid:39121849</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.036</dc:identifier>
</item>
<item>
<title>LAG-3 and PD-1 synergize on CD8&lt;sup>;+&lt;/sup>; T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121848/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in its class to be FDA approved. However, how these two inhibitory receptors synergize to hinder anti-tumor immunity remains unknown. Here, we show that CD8^(+) T cells deficient in both PD-1 and LAG-3, in contrast to CD8^(+) T cells lacking either receptor,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4355-4372.e22. doi: 10.1016/j.cell.2024.07.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in its class to be FDA approved. However, how these two inhibitory receptors synergize to hinder anti-tumor immunity remains unknown. Here, we show that CD8<sup>+</sup> T cells deficient in both PD-1 and LAG-3, in contrast to CD8<sup>+</sup> T cells lacking either receptor, mediate enhanced tumor clearance and long-term survival in mouse models of melanoma. PD-1- and LAG-3-deficient CD8<sup>+</sup> T cells were transcriptionally distinct, with broad TCR clonality and enrichment of effector-like and interferon-responsive genes, resulting in enhanced IFN-γ release indicative of functionality. LAG-3 and PD-1 combined to drive T cell exhaustion, playing a dominant role in modulating TOX expression. Mechanistically, autocrine, cell-intrinsic IFN-γ signaling was required for PD-1- and LAG-3-deficient CD8<sup>+</sup> T cells to enhance anti-tumor immunity, providing insight into how combinatorial targeting of LAG-3 and PD-1 enhances efficacy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121848</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.016>10.1016/j.cell.2024.07.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121848</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Lawrence P Andrews</dc:creator>
<dc:creator>Samuel C Butler</dc:creator>
<dc:creator>Jian Cui</dc:creator>
<dc:creator>Anthony R Cillo</dc:creator>
<dc:creator>Carly Cardello</dc:creator>
<dc:creator>Chang Liu</dc:creator>
<dc:creator>Erin A Brunazzi</dc:creator>
<dc:creator>Andrew Baessler</dc:creator>
<dc:creator>Bingxian Xie</dc:creator>
<dc:creator>Sheryl R Kunning</dc:creator>
<dc:creator>Shin Foong Ngiow</dc:creator>
<dc:creator>Yinghui Jane Huang</dc:creator>
<dc:creator>Sasikanth Manne</dc:creator>
<dc:creator>Arlene H Sharpe</dc:creator>
<dc:creator>Greg M Delgoffe</dc:creator>
<dc:creator>E John Wherry</dc:creator>
<dc:creator>John M Kirkwood</dc:creator>
<dc:creator>Tulia C Bruno</dc:creator>
<dc:creator>Creg J Workman</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>LAG-3 and PD-1 synergize on CD8&lt;sup>;+&lt;/sup>; T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity</dc:title>
<dc:identifier>pmid:39121848</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.016</dc:identifier>
</item>
<item>
<title>LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121847/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>Exhausted CD8 T (T(ex)) cells in chronic viral infection and cancer have sustained co-expression of inhibitory receptors (IRs). T(ex) cells can be reinvigorated by blocking IRs, such as PD-1, but synergistic reinvigoration and enhanced disease control can be achieved by co-targeting multiple IRs including PD-1 and LAG-3. To dissect the molecular changes intrinsic when these IR pathways are disrupted, we investigated the impact of loss of PD-1 and/or LAG-3 on T(ex) cells during chronic infection....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4336-4354.e19. doi: 10.1016/j.cell.2024.07.018.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Exhausted CD8 T (T<sub>ex</sub>) cells in chronic viral infection and cancer have sustained co-expression of inhibitory receptors (IRs). T<sub>ex</sub> cells can be reinvigorated by blocking IRs, such as PD-1, but synergistic reinvigoration and enhanced disease control can be achieved by co-targeting multiple IRs including PD-1 and LAG-3. To dissect the molecular changes intrinsic when these IR pathways are disrupted, we investigated the impact of loss of PD-1 and/or LAG-3 on T<sub>ex</sub> cells during chronic infection. These analyses revealed distinct roles of PD-1 and LAG-3 in regulating T<sub>ex</sub> cell proliferation and effector functions, respectively. Moreover, these studies identified an essential role for LAG-3 in sustaining TOX and T<sub>ex</sub> cell durability as well as a LAG-3-dependent circuit that generated a CD94/NKG2<sup>+</sup> subset of T<sub>ex</sub> cells with enhanced cytotoxicity mediated by recognition of the stress ligand Qa-1b, with similar observations in humans. These analyses disentangle the non-redundant mechanisms of PD-1 and LAG-3 and their synergy in regulating T<sub>ex</sub> cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121847/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121847</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.018>10.1016/j.cell.2024.07.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121847</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Shin Foong Ngiow</dc:creator>
<dc:creator>Sasikanth Manne</dc:creator>
<dc:creator>Yinghui Jane Huang</dc:creator>
<dc:creator>Tarek Azar</dc:creator>
<dc:creator>Zeyu Chen</dc:creator>
<dc:creator>Divij Mathew</dc:creator>
<dc:creator>Qingzhou Chen</dc:creator>
<dc:creator>Omar Khan</dc:creator>
<dc:creator>Jennifer E Wu</dc:creator>
<dc:creator>Victor Alcalde</dc:creator>
<dc:creator>Ahron J Flowers</dc:creator>
<dc:creator>Sean McClain</dc:creator>
<dc:creator>Amy E Baxter</dc:creator>
<dc:creator>Makoto Kurachi</dc:creator>
<dc:creator>Junwei Shi</dc:creator>
<dc:creator>Alexander C Huang</dc:creator>
<dc:creator>Josephine R Giles</dc:creator>
<dc:creator>Arlene H Sharpe</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:creator>E John Wherry</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity</dc:title>
<dc:identifier>pmid:39121847</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.018</dc:identifier>
</item>
<item>
<title>Guidelines for minimal information on cellular senescence experimentation in vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121846/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>Cellular senescence is a cell fate triggered in response to stress and is characterized by stable cell-cycle arrest and a hypersecretory state. It has diverse biological roles, ranging from tissue repair to chronic disease. The development of new tools to study senescence in vivo has paved the way for uncovering its physiological and pathological roles and testing senescent cells as a therapeutic target. However, the lack of specific and broadly applicable markers makes it difficult to identify...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4150-4175. doi: 10.1016/j.cell.2024.05.059.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cellular senescence is a cell fate triggered in response to stress and is characterized by stable cell-cycle arrest and a hypersecretory state. It has diverse biological roles, ranging from tissue repair to chronic disease. The development of new tools to study senescence in vivo has paved the way for uncovering its physiological and pathological roles and testing senescent cells as a therapeutic target. However, the lack of specific and broadly applicable markers makes it difficult to identify and characterize senescent cells in tissues and living organisms. To address this, we provide practical guidelines called "minimum information for cellular senescence experimentation in vivo" (MICSE). It presents an overview of senescence markers in rodent tissues, transgenic models, non-mammalian systems, human tissues, and tumors and their use in the identification and specification of senescent cells. These guidelines provide a uniform, state-of-the-art, and accessible toolset to improve our understanding of cellular senescence in vivo.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121846/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121846</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.059>10.1016/j.cell.2024.05.059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121846</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Mikolaj Ogrodnik</dc:creator>
<dc:creator>Juan Carlos Acosta</dc:creator>
<dc:creator>Peter D Adams</dc:creator>
<dc:creator>Fabrizio d'Adda di Fagagna</dc:creator>
<dc:creator>Darren J Baker</dc:creator>
<dc:creator>Cleo L Bishop</dc:creator>
<dc:creator>Tamir Chandra</dc:creator>
<dc:creator>Manuel Collado</dc:creator>
<dc:creator>Jesus Gil</dc:creator>
<dc:creator>Vassilis Gorgoulis</dc:creator>
<dc:creator>Florian Gruber</dc:creator>
<dc:creator>Eiji Hara</dc:creator>
<dc:creator>Pidder Jansen-Dürr</dc:creator>
<dc:creator>Diana Jurk</dc:creator>
<dc:creator>Sundeep Khosla</dc:creator>
<dc:creator>James L Kirkland</dc:creator>
<dc:creator>Valery Krizhanovsky</dc:creator>
<dc:creator>Tohru Minamino</dc:creator>
<dc:creator>Laura J Niedernhofer</dc:creator>
<dc:creator>João F Passos</dc:creator>
<dc:creator>Nadja A R Ring</dc:creator>
<dc:creator>Heinz Redl</dc:creator>
<dc:creator>Paul D Robbins</dc:creator>
<dc:creator>Francis Rodier</dc:creator>
<dc:creator>Karin Scharffetter-Kochanek</dc:creator>
<dc:creator>John M Sedivy</dc:creator>
<dc:creator>Ewa Sikora</dc:creator>
<dc:creator>Kenneth Witwer</dc:creator>
<dc:creator>Thomas von Zglinicki</dc:creator>
<dc:creator>Maximina H Yun</dc:creator>
<dc:creator>Johannes Grillari</dc:creator>
<dc:creator>Marco Demaria</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Guidelines for minimal information on cellular senescence experimentation in vivo</dc:title>
<dc:identifier>pmid:39121846</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.059</dc:identifier>
</item>
<item>
<title>Prying the lid open: Atomic-level insights on sialoglycan-TMPRSS2 coordination in HKU1 entry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121845/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>The pre-fusion coronavirus HKU1 spike binds host sialoglycans and proteinaceous receptor TMPRSS2 for cell entry. In this issue of Cell, three papers by Fernández et al., McCallum et al., and Wang et al. provide structural information on HKU1 spike interactions with host receptors, providing insights into its multi-step opening.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4147-4149. doi: 10.1016/j.cell.2024.07.007.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The pre-fusion coronavirus HKU1 spike binds host sialoglycans and proteinaceous receptor TMPRSS2 for cell entry. In this issue of Cell, three papers by Fernández et al., McCallum et al., and Wang et al. provide structural information on HKU1 spike interactions with host receptors, providing insights into its multi-step opening.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121845/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121845</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.007>10.1016/j.cell.2024.07.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121845</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Ruth J Parsons</dc:creator>
<dc:creator>Priyamvada Acharya</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Prying the lid open: Atomic-level insights on sialoglycan-TMPRSS2 coordination in HKU1 entry</dc:title>
<dc:identifier>pmid:39121845</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.007</dc:identifier>
</item>
<item>
<title>Anti-LAG-3 boosts CD8 T cell effector function</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 8;187(16):4144-4146. doi: 10.1016/j.cell.2024.07.004.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121844</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.004>10.1016/j.cell.2024.07.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121844</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Courtney T Kureshi</dc:creator>
<dc:creator>Michael Dougan</dc:creator>
<dc:creator>Stephanie K Dougan</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Anti-LAG-3 boosts CD8 T cell effector function</dc:title>
<dc:identifier>pmid:39121844</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.004</dc:identifier>
</item>
<item>
<title>Heart failure and ischaemic heart disease: new challenges and opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39121015/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 9;45(30):2681-2685. doi: 10.1093/eurheartj/ehae497.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39121015/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39121015</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae497>10.1093/eurheartj/ehae497</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39121015</guid>
<pubDate>Fri, 09 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-08-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Heart failure and ischaemic heart disease: new challenges and opportunities</dc:title>
<dc:identifier>pmid:39121015</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae497</dc:identifier>
</item>
<item>
<title>Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115523/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 2:S0735-1097(24)07774-X. doi: 10.1016/j.jacc.2024.06.026. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115523/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39115523</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.026>10.1016/j.jacc.2024.06.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115523</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>João Sérgio Neves</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF?</dc:title>
<dc:identifier>pmid:39115523</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.026</dc:identifier>
</item>
<item>
<title>Training of the adult congenital cardiac interventionalist: a call to action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115082/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 8:ehae495. doi: 10.1093/eurheartj/ehae495. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115082/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39115082</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae495>10.1093/eurheartj/ehae495</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115082</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Jamil Aboulhosn</dc:creator>
<dc:creator>Carlos Pedra</dc:creator>
<dc:creator>Eric Horlick</dc:creator>
<dc:creator>Teiji Akagi</dc:creator>
<dc:creator>Massimo Chessa</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Training of the adult congenital cardiac interventionalist: a call to action</dc:title>
<dc:identifier>pmid:39115082</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae495</dc:identifier>
</item>
<item>
<title>KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 8:ehae476. doi: 10.1093/eurheartj/ehae476. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P &lt; .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39115049</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae476>10.1093/eurheartj/ehae476</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115049</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sahej Bains</dc:creator>
<dc:creator>Lucilla Giammarino</dc:creator>
<dc:creator>Saranda Nimani</dc:creator>
<dc:creator>Nicolo Alerni</dc:creator>
<dc:creator>David J Tester</dc:creator>
<dc:creator>C S John Kim</dc:creator>
<dc:creator>Nicolas Christoforou</dc:creator>
<dc:creator>Julien Louradour</dc:creator>
<dc:creator>András Horváth</dc:creator>
<dc:creator>Olgica Beslac</dc:creator>
<dc:creator>Miriam Barbieri</dc:creator>
<dc:creator>Lluis Matas</dc:creator>
<dc:creator>Thomas S Hof</dc:creator>
<dc:creator>Ruben Lopez</dc:creator>
<dc:creator>Stefanie Perez-Feliz</dc:creator>
<dc:creator>Chiara Parodi</dc:creator>
<dc:creator>Luisana G Garcia Casalta</dc:creator>
<dc:creator>Jacqulyn Jurgensen</dc:creator>
<dc:creator>Michael A Barry</dc:creator>
<dc:creator>Mariana Bego</dc:creator>
<dc:creator>Lisa Keyes</dc:creator>
<dc:creator>Jane Owens</dc:creator>
<dc:creator>Jason Pinkstaff</dc:creator>
<dc:creator>Gideon Koren</dc:creator>
<dc:creator>Manfred Zehender</dc:creator>
<dc:creator>Michael Brunner</dc:creator>
<dc:creator>Daniela Casoni</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Andreas Haeberlin</dc:creator>
<dc:creator>Gabriel Brooks</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Katja E Odening</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome</dc:title>
<dc:identifier>pmid:39115049</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae476</dc:identifier>
</item>
<item>
<title>Metabolites regulating chromatin accessibility: a piece of the puzzle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39115023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Aug 8:ehae468. doi: 10.1093/eurheartj/ehae468. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39115023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39115023</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae468>10.1093/eurheartj/ehae468</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39115023</guid>
<pubDate>Thu, 08 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Nicolle Kränkel</dc:creator>
<dc:date>2024-08-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Metabolites regulating chromatin accessibility: a piece of the puzzle</dc:title>
<dc:identifier>pmid:39115023</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae468</dc:identifier>
</item>
<item>
<title>Stroke triggers an innate immune memory that drives cardiac dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39112562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Aug 7. doi: 10.1038/s41569-024-01069-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39112562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39112562</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01069-z>10.1038/s41569-024-01069-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39112562</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Stroke triggers an innate immune memory that drives cardiac dysfunction</dc:title>
<dc:identifier>pmid:39112562</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01069-z</dc:identifier>
</item>
<item>
<title>Mechanisms and treatment of pulmonary arterial hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39112561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Aug 7. doi: 10.1038/s41569-024-01064-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Substantial progress has been made in the management of pulmonary arterial hypertension (PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for PAH are mostly limited to symptomatic relief by correcting the imbalance of vasoactive factors. The tyrosine kinase inhibitor imatinib, the first predominantly non-vasodilatory drug to be tested in patients with PAH, improved exercise capacity and pulmonary haemodynamics compared with placebo but at the expense of adverse events such as subdural haematoma. Given that administration by inhalation might reduce the risk of systemic adverse effects, inhaled formulations of tyrosine kinase inhibitors are currently in clinical development. Other novel therapeutic approaches for PAH include suppression of activin receptor type IIA signalling with sotatercept, which has shown substantial efficacy in clinical trials and was approved for use in the USA in 2024, but the long-term safety of the drug remains unclear. Future advances in the management of PAH will focus on right ventricular function and involve deep phenotyping and the development of a personalized medicine approach. In this Review, we summarize the mechanisms underlying PAH, provide an overview of available PAH therapies and their limitations, describe the development of newer, predominantly non-vasodilatory drugs that are currently being tested in phase II or III clinical trials, and discuss future directions for PAH research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39112561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39112561</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01064-4>10.1038/s41569-024-01064-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39112561</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Hossein-Ardeschir Ghofrani</dc:creator>
<dc:creator>Mardi Gomberg-Maitland</dc:creator>
<dc:creator>Lan Zhao</dc:creator>
<dc:creator>Friedrich Grimminger</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Mechanisms and treatment of pulmonary arterial hypertension</dc:title>
<dc:identifier>pmid:39112561</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01064-4</dc:identifier>
</item>
<item>
<title>Active-Duty Sailor Develops PFO-Associated Decompression Sickness: Do Occupational Divers Warrant Alternative Cardiac Screening Standards?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>We report a case of an active-duty diver who developed severe decompression sickness with concomitant patent foramen ovale that was successfully closed contrary to standard guideline recommendations. This case should prompt evaluation of the role of cardiac screening in occupational divers, including tactical athletes, relative to recreational divers.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):678-682. doi: 10.1016/j.jacc.2024.06.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We report a case of an active-duty diver who developed severe decompression sickness with concomitant patent foramen ovale that was successfully closed contrary to standard guideline recommendations. This case should prompt evaluation of the role of cardiac screening in occupational divers, including tactical athletes, relative to recreational divers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39111976</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.010>10.1016/j.jacc.2024.06.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111976</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tarin C Phillips</dc:creator>
<dc:creator>W Rainey Johnson</dc:creator>
<dc:creator>Nitin L Rao</dc:creator>
<dc:creator>Caroline E Murphy</dc:creator>
<dc:creator>Robert M Gallagher</dc:creator>
<dc:creator>Sonya N Waters</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Active-Duty Sailor Develops PFO-Associated Decompression Sickness: Do Occupational Divers Warrant Alternative Cardiac Screening Standards?</dc:title>
<dc:identifier>pmid:39111976</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.010</dc:identifier>
</item>
<item>
<title>Safety of Direct Current Cardioversion Without Routine Transesophageal Echocardiography in Patients With Cardiac Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):675-677. doi: 10.1016/j.jacc.2024.04.066.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39111975</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.066>10.1016/j.jacc.2024.04.066</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111975</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Osnat Itzhaki Ben Zadok</dc:creator>
<dc:creator>Sarah A M Cuddy</dc:creator>
<dc:creator>Hannah K Gaggin</dc:creator>
<dc:creator>Olivier F Clerc</dc:creator>
<dc:creator>Shilpa Vijayakumar</dc:creator>
<dc:creator>Sharmila Dorbala</dc:creator>
<dc:creator>Rodney H Falk</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Safety of Direct Current Cardioversion Without Routine Transesophageal Echocardiography in Patients With Cardiac Amyloidosis</dc:title>
<dc:identifier>pmid:39111975</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.066</dc:identifier>
</item>
<item>
<title>Ending Trans Fat-The First-Ever Global Elimination Program for a Noncommunicable Disease Risk Factor: JACC International</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111974/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>Industrially produced trans fat (iTFA) is a harmful compound created as a substitute for animal and saturated fats. Estimated to cause up to 500,000 deaths per year, it is replaceable. In 2018, Resolve to Save Lives, the World Health Organization (WHO), Global Health Advocacy Incubator, and NCD Alliance partnered to achieve global trans fat elimination. The WHO Director-General called for the elimination of trans fat by 2023 through best practice policies outlined in the WHO REPLACE package....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):663-674. doi: 10.1016/j.jacc.2024.04.067.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Industrially produced trans fat (iTFA) is a harmful compound created as a substitute for animal and saturated fats. Estimated to cause up to 500,000 deaths per year, it is replaceable. In 2018, Resolve to Save Lives, the World Health Organization (WHO), Global Health Advocacy Incubator, and NCD Alliance partnered to achieve global trans fat elimination. The WHO Director-General called for the elimination of trans fat by 2023 through best practice policies outlined in the WHO REPLACE package. Since the accelerated global efforts in 2018, 43 countries have adopted best practice regulations protecting an additional 3.2 billion people and building momentum toward global elimination. Current coverage will prevent 66% of deaths estimated to be caused each year by trans fat in foods. Despite producing and selling iTFA-free products in many countries, companies continue to sell iTFA-containing products in unregulated markets. Global incentives, accountability mechanisms, and regional policies will help achieve the elimination goal.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111974/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39111974</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.067>10.1016/j.jacc.2024.04.067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111974</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Lindsay Steele</dc:creator>
<dc:creator>Elizabeth Drummond</dc:creator>
<dc:creator>Chizuru Nishida</dc:creator>
<dc:creator>Rain Yamamoto</dc:creator>
<dc:creator>Francesco Branca</dc:creator>
<dc:creator>Cristina Parsons Perez</dc:creator>
<dc:creator>Lorena Allemandi</dc:creator>
<dc:creator>Liz Arnanz</dc:creator>
<dc:creator>Veronica Schoj</dc:creator>
<dc:creator>Hema S Khanchandani</dc:creator>
<dc:creator>Swati Bhardwaj</dc:creator>
<dc:creator>Renu Garg</dc:creator>
<dc:creator>Thomas R Frieden</dc:creator>
<dc:creator>Laura K Cobb</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ending Trans Fat-The First-Ever Global Elimination Program for a Noncommunicable Disease Risk Factor: JACC International</dc:title>
<dc:identifier>pmid:39111974</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.067</dc:identifier>
</item>
<item>
<title>Use of Feature Tracking to Predict Outcome in Epidemiologic Studies Using Cardiac Magnetic Resonance Imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111973/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):660-662. doi: 10.1016/j.jacc.2024.05.052.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111973/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39111973</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.052>10.1016/j.jacc.2024.05.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111973</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas Marwick</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Use of Feature Tracking to Predict Outcome in Epidemiologic Studies Using Cardiac Magnetic Resonance Imaging</dc:title>
<dc:identifier>pmid:39111973</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.052</dc:identifier>
</item>
<item>
<title>Myocardial Strain Measured by Cardiac Magnetic Resonance Predicts Cardiovascular Morbidity and Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39111972/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240811001215&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the general population, LV strain metrics derived using CMR-FT in radial, circumferential, and longitudinal directions are strongly and independently predictive of heart failure, myocardial infarction, and stroke, but only GLS is independently predictive of death in an adult population cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 13;84(7):648-659. doi: 10.1016/j.jacc.2024.05.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myocardial strain using cardiac magnetic resonance (CMR) is a sensitive marker for predicting adverse outcomes in many cardiac disease states, but the prognostic value in the general population has not been studied conclusively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to assess the independent prognostic value of CMR feature tracking (FT)-derived LV global longitudinal (GLS), circumferential (GCS), and radial strain (GRS) metrics in predicting adverse outcomes (heart failure, myocardial infarction, stroke, and death).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Participants from the UK Biobank population imaging study were included. Univariable and multivariable Cox models were used for each outcome and each strain marker (GLS, GCS, GRS) separately. The multivariable models were tested with adjustment for prognostically important clinical features and conventional global LV imaging markers relevant for each outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 45,700 participants were included in the study (average age 65 ± 8 years), with a median follow-up period of 3 years. All univariable and multivariable models demonstrated that lower absolute GLS, GCS, and GRS were associated with increased incidence of heart failure, myocardial infarction, stroke, and death. All strain markers were independent predictors (incrementally above some respective conventional LV imaging markers) for the morbidity outcomes, but only GLS predicted death independently: (HR: 1.18; 95% CI: 1.07-1.30).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the general population, LV strain metrics derived using CMR-FT in radial, circumferential, and longitudinal directions are strongly and independently predictive of heart failure, myocardial infarction, and stroke, but only GLS is independently predictive of death in an adult population cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39111972/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240811001215&v=2.18.0.post9+e462414">39111972</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.050>10.1016/j.jacc.2024.05.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39111972</guid>
<pubDate>Wed, 07 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Sucharitha Chadalavada</dc:creator>
<dc:creator>Kenneth Fung</dc:creator>
<dc:creator>Elisa Rauseo</dc:creator>
<dc:creator>Aaron M Lee</dc:creator>
<dc:creator>Mohammed Y Khanji</dc:creator>
<dc:creator>Alborz Amir-Khalili</dc:creator>
<dc:creator>Jose Paiva</dc:creator>
<dc:creator>Hafiz Naderi</dc:creator>
<dc:creator>Shantanu Banik</dc:creator>
<dc:creator>Mihaela Chirvasa</dc:creator>
<dc:creator>Magnus T Jensen</dc:creator>
<dc:creator>Nay Aung</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:date>2024-08-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Myocardial Strain Measured by Cardiac Magnetic Resonance Predicts Cardiovascular Morbidity and Death</dc:title>
<dc:identifier>pmid:39111972</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.050</dc:identifier>
</item>





























</channel>
</rss>